uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Use of rivaroxaban in Germany: a database drug utilization study of a drug started in hospital
Show others and affiliations
2014 (English)In: European Journal of Clinical Pharmacology, ISSN 0031-6970, E-ISSN 1432-1041, Vol. 70, no 8, 975-981 p.Article in journal (Refereed) Published
Abstract [en]

The purpose of this drug utilization study was to describe the use of rivaroxaban in Germany during a time period in which approval was limited to the prevention of venous thromboembolism following hip or knee replacement. Additionally, we explored the feasibility of reconstructing inpatient drug use of rivaroxaban in a database where with a few exceptions inpatient prescribing information is not available. Source of data was one statutory health insurance providing data on about seven million insurants throughout Germany. Analyses were based on a cohort of rivaroxaban users from launch (October 2008) to December 2009 and encompassed potential indications for rivaroxaban use, treatment duration, and co-prescribing of potentially interacting drugs. Start of rivaroxaban treatment was defined by the date of surgery. During the study period, 425 rivaroxaban users were identified contributing 440 treatment periods. For more than 82 % of these episodes labelled indications could be determined. Treatment durations exceeded recommendations in 95 % of the episodes following knee replacement whereas rivaroxaban use after elective hip surgery was found to be longer than recommended in 56 %. Prescribing of potentially interacting medication was rare except for non-steroidal anti-inflammatory drugs. Overall, no important off-label use of rivaroxaban was identified. Based on several assumptions that have to be considered in the interpretation of the results our study describes a database approach to reconstruct inpatient drug use for a drug started after a coded hospital procedure, when treatment continues after hospital discharge and no change in drug use is expected in the outpatient setting.

Place, publisher, year, edition, pages
2014. Vol. 70, no 8, 975-981 p.
Keyword [en]
Rivaroxaban, Drug utilization, Inpatient drug use, German Pharmacoepidemiological Research Database
National Category
Medical and Health Sciences
Identifiers
URN: urn:nbn:se:uu:diva-230070DOI: 10.1007/s00228-014-1697-7ISI: 000339332700011PubMedID: 24858823OAI: oai:DiVA.org:uu-230070DiVA: diva2:743234
Available from: 2014-09-03 Created: 2014-08-19 Last updated: 2017-12-05Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Authority records BETA

Wallander, Mari-Ann

Search in DiVA

By author/editor
Wallander, Mari-Ann
By organisation
Family Medicine and Preventive Medicine
In the same journal
European Journal of Clinical Pharmacology
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 396 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf